Sequenom Laboratories Announces Third National Coverage Agreement For Prenatal Diagnostic Testing Services

Sequenom Laboratories Announces Third National Coverage Agreement For Prenatal
                         Diagnostic Testing Services

PR Newswire

SAN DIEGO, June 9, 2014

SAN DIEGO, June 9, 2014 /PRNewswire/ --Sequenom, Inc. (NASDAQ: SQNM), a life
sciences company providing innovative testing and genetic analysis solutions,
announced today its wholly owned subsidiary, Sequenom Laboratories, has signed
a national agreement with a leading health insurance company covering 13
million people throughout the United States, to provide the MaterniT21™ PLUS
laboratory-developed test (LDT). The addition of this contract brings the
number of covered lives under agreement by Sequenom Laboratories' diagnostic
services to more than 140 million.

"This new payor agreement is a testament to the continued acceptance and
adoption of noninvasive prenatal testing (NIPT), and we are proud to maintain
our position as a market leader in this innovative and rapidly growing area,"
said William Welch, President and Chief Operating Officer of Sequenom. "Now,
even more expectant women at high risk for fetal aneuploidy and their families
will have access to the MaterniT21 PLUS test in the U.S., and we believe these
patients and the physicians that treat them will continue to find value in the
accurate and timely information provided by the MaterniT21 PLUS test."

The MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13, as well
as Y chromosomal material in cell-free DNA. The test also reports additional
findings for the presence of sex subchromosomal aneuploidies, trisomy 16 and
22, subchromosomal microdeletions and duplications which complement the
MaterniT21 PLUS test core findings.The test is intended for use in pregnant
women at increased risk for fetal chromosomal abnormalities and is indicated
for use as early as 10 weeks' gestation. Estimates suggest there are about
750,000 pregnancies at high risk for fetal chromosomal abnormalities each year
in the United States.

The MaterniT21 PLUS test is available exclusively through Sequenom
Laboratories as a testing service provided to health care professionals. To
learn more about the test, please visit

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genomic and genetic analysis
solutions. Sequenom develops innovative technology, products and diagnostic
tests that target and serve molecular diagnostic markets. Website:

About Sequenom Laboratories
Sequenom Laboratories, a CAP accredited and CLIA-certified molecular
diagnostics laboratory, has developed a broad range of laboratory-developed
tests, with a focus on prenatal and ophthalmological diseases and conditions.
Branded under the names SensiGene™, MaterniT21™ PLUS, HerediT™, NextView™ and
RetnaGene™, these molecular genetic laboratory-developed tests provide early
patient management information for obstetricians, geneticists, maternal fetal
medicine specialists and ophthalmologists. Sequenom Laboratories is changing
the landscape in genetic disorder diagnostics using proprietary cutting edge

SEQUENOM®, MaterniT21™ PLUS, SensiGene™, HerediT™, NextView™ and RetnaGene™
are trademarks of Sequenom, Inc. All other trademarks and service marks are
the property of their respective owners.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding the market's continued
acceptance and adoption of noninvasive prenatal testing, access to the
MaterniT21 PLUS test and the benefits and impact of the test and the payor
agreement on patients, their families, and physicians, are forward-looking
statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to differ
materially, including the risks and uncertainties associated with reliance
upon the collaborative efforts of the national payor, Sequenom's ability to
develop and commercialize new technologies and products, particularly new
technologies such as prenatal and other diagnostics and laboratory developed
tests, Sequenom's ability to manage its existing cash resources or raise
additional cash resources, competition, intellectual property protection and
intellectual property rights of others, government regulation particularly
with respect to diagnostic products and laboratory-developed tests, obtaining
or maintaining regulatory approvals, ongoing litigation including patent
litigation, and other risks detailed from time to time in Sequenom, Inc.'s
most recent Quarterly and Annual Reports on Securities and Exchange Commission
Forms 10-Q and 10-K, respectively, and other documents subsequently filed with
or furnished to the Securities and Exchange Commission. These forward-looking
statements are based on current information that may change and you are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. All forward-looking
statements are qualified in their entirety by this cautionary statement, and
Sequenom undertakes no obligation to revise or update any forward-looking
statement to reflect events or circumstances after the issuance of this press


Logo -

SOURCE Sequenom, Inc.

Contact: Paul Maier, Chief Financial Officer, Sequenom, Inc., 858-202-9028,; Rachel Kennedy, Media Contact, Chandler Chicco
Agency, 858-449-9575,
Press spacebar to pause and continue. Press esc to stop.